Fate Therapeutics Major Shareholder Venture Fund Vi Lp Arch Purchases 833,333 Shares (FATE)
Fate Therapeutics (NASDAQ:FATE) major shareholder Venture Fund Vi Lp Arch acquired 833,333 shares of the stock on the open market in a transaction dated Friday, October 4th. The stock was purchased at an average cost of $6.00 per share, with a total value of $4,999,998.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Fate Therapeutics (NASDAQ:FATE) traded up 24.06% on Monday, hitting $8.87. The stock had a trading volume of 315,331 shares. Fate Therapeutics has a one year low of $6.31 and a one year high of $7.24. The stock has a 50-day moving average of $6.9 and a 200-day moving average of $6.9. The company’s market cap is $169.9 million.
Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.